Improve Patient Outcomes

Faster targeted therapy can save lives

Improving patient outcomes is at the heart of T2 Biosystems’ mission. Studies have demonstrated that faster targeted therapy for sepsis patients saves lives – cutting the mortality rate in half.1

Today, empiric therapy misses 40% of sepsis patients.2 T2Direct Diagnostics™ provide faster species identification of many of the most common and deadly sepsis-causing pathogens, allowing earlier targeted therapy. Earlier targeted therapy for these pathogens may prevent may prevent a bloodstream infection from progressing to sepsis. In addition, the ability to quickly rule-out clinically important pathogens can positively impact patient management.

A study published in Future Microbiology, found that the T2Candida Panel could potentially lead to a reduction of 60.6% Candida-related deaths per hospital.3

T2Direct Diagnostics – Proven to Deliver Improved Patient Outcomes

  • Henry Ford Health System in Michigan reduced the median ICU length of stay per patient by 7 days and showed a trend in reducing total length of stay (LOS) by an average of 4 days per patient.4 In addition, 75% of negative patients had antifungals discontinued or de-escalated.   
  • Lee Health System in Florida experienced a reduction in length of stay (LOS) by an average of 7 days.5
  • At Huntsville Hospital in Alabama, approximately two-thirds of patients with negative T2 results experienced reduced antifungal therapy – and negative results decreased the use of micafungin by more than 2 days.

Watch the Henry Ford Health System webinar on implementation and patient outcomes.

Request a T2Direct Diagnostics meeting.


1. Leibovici, L., Shraga, I., Drucker, M., et al. (1998). The benefit of appropriate empirical antibiotic treatment in patients with bloodstream infection. Journal of internal medicine, 244(5), 379-386.
2. Buehler, S.S., Madison, B., Snyder, S.R., et al. (2016). Effectiveness of practices to increase timeliness of providing targeted therapy for inpatients with bloodstream infections: A laboratory medicine best practices systematic review and meta-analysis. Clinical microbiology reviews, 29(1), 59-103.
3. Bilir, S.P., Ferrufino, C.P., Pfaller, M.A., and Munakata, J. (2015). The economic impact of rapid Candida species identification by T2Candida among high-risk patients. Future microbiology, (10) 7,1133-1144. – 2015
4. Wilson, N.M., Kenney, R.M.,  Tibbetts, R.J., et. al. T2 Magnetic Resonance Improves the timely management of candidemia. Poster Presentation IDWeek 2016.
5. Estrada, S.J. Real World Value of T2Candida Lee Memorial Hospital. Slide Presentation ASM 2016.